Challenging paradigms in lymphoma treatment

Annals of Oncology

Volumn 15, Issue 5, 2004, Pages 703-711

  Bendandi, M ^a   Pileri, S A ^b   Zinzani, P L ^b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Lymphoma classification; Lymphoma treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; INTERLEUKIN 2; LOMUSTINE; MELPHALAN; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMACH LYMPHOMA; VACCINATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HODGKIN DISEASE; HUMANS; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; PATIENT CARE PLANNING; PROGNOSIS; RADIOTHERAPY;

EID: 2642537843     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh094     Document Type: Review

References (110)

1. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
2. Isaacson PG, Muller-Hermelink HK, Piris MA et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Jaffe ES, Harris NL, Stein H et al. (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press 2001; 157-160.
3. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
4. Solal-Celigny P. Follicular Lymphoma International Prognostic Project (FLIPP). Ann Oncol 2002; 13 (Suppl 2): 25.
5. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 13-14.
6. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
7. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
8. Horning SJ, Hoppe RT, Breslin S et al. Stanford V and radiation treatment for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630-37.
9. Canellos GP. New treatments for advanced Hodgkin's disease: an uphill fight beginning close to the top. J Clin Oncol 2002; 20: 607-609.
10. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-1514.
11. Hasenclever D. The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol 2002; 13: 75-78.
12. Longo DL. Radiation therapy in the treatment of Hodgkin's disease: do you see what I see? J Natl Cancer Inst 2003; 95: 928-929.
13. Tarella C, Caracciolo D, Corradini P et al. Long-term follow-up of advanced-stage low-grade lymphoma patients treated up front with high-dose sequential chemotherapy and autograft. Leukemia 2000; 14: 740-747.
14. Horning SJ, Negrin RS, Hoppe RT et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001; 97: 404-409.
15. Freedman AS, Gribben JG, Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780-2786.
16. Corradini P, Tarella C, Olivieri A et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99: 75-82.
17. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918-3924.
18. Press OW, LeBlanc M, Lichter AS et al. Phase III randomized intergroup trial of subtotal lymphoid irrdiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001; 19: 4238-4244.
19. Sieber M, Tesch H, Pfistner B et al. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiation treatment in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol 2002; 20: 476-484.
20. Levis A, Gobbi PG, Chisesi M et al. ABVD vs Stanford V vs MOPP-EBV-CAD in advanced Hodgkin's lymphoma. Results of a randomized trial. Ann Oncol 2002; 13 (Suppl 2): 25.
21. Radford JA, Rohatiner AZ, Ryder WD et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 2002; 20: 2988-2994.
22. Josting A, Wiedenmann S, Franklin J et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3440-3446.
23. Zinzani PL, Magagnoli M, Bendandi M et al. Efficacy of the VBM regimen in the treatment of elderly patients with Hodgkin's disease. Haematologica 2000; 85: 729-732.
24. Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-2934.
25. Spaepen K, Stroobants S, Dupont P et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1356-1363.
26. Aleman BM, Raemaekers JM, Tirelli U et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348: 2396-2406.
27. Josting A, Rueffer U, Franklin J et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96: 1280-1286.
28. Josting A, Franklin J, May M et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2002; 20: 221-230.
29. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial. Lancet 2002; 359: 2065-2071.
30. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
31. Miller TP, Dahlberg S, Fisher RI et al. Chemotherapy alone compared with chemotherapy plus radiation treatment for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21-26.
32. Fillet G, Bonnet G, Mounier N et al. Radiotherapy is unnecessary in elderly patients with localized aggresive non-Hodgkin's lymphoma: results of GELA LNH 93-4 study. Blood 2002; 100 (Suppl 1): 92a.
33. Miller TP, LeBlanc M, Spier C et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphoma: update of the Southwest Oncology Group (SWOG) randomized trial. Blood 2001; 98 (Suppl 1): 724a.
34. Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389-397.
35. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
36. Mainwaring PN, Cunningham D, Gregory W et al. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO. Blood 2001; 97: 2991-2997.
37. Wilder RB, Rodriguez MA, Medeiros LJ et al. International Prognostic Index-based outcomes for diffuse large B-cell lymphomas. Cancer 2002; 94: 3083-3088.
38. Wilson WH, Grossbard ML, Pittaluga S et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99: 2685-2693.
39. Huang JZ, Sanger WG, Greiner TC et al. The t(14; 18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 2285-2290.
40. Yamaguchi M, Seto M, Okamoto M et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99: 815-821.
41. Staudt LM, Wilson WH. Focus on lymphomas. Cancer Cell 2002; 2: 363-366.
42. Wirth A, Seymour JF, Hicks RJ et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non Hodgkin's lymphoma. Am J Med 2002; 112: 262-268.
43. Haioun C, Itti E, Rahmouni A et al. 18F-fluorodesoxyglucose positron emission tomography (FDG-PET) in aggressive non-Hodgkin's lymphoma. (NHL): an early prognostic tool for predicting patient outcome. J Clin Oncol 2003; 22 (Suppl 1): 2274a.
44. Press OW, Eary JF, Gooley T et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934-2942.
45. Philip T, Chauvin F, Armitage J et al. PARMA International Protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991; 77: 587-592.
46. Kewalramani T, Zelenetz AD, Hedrick EE et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2002; 96: 2399-2404.
47. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025-3030.
48. Vose JM, Sharp G, Chan WC et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002; 20: 2344-2352.
49. Ladetto M, Zallio F, Vallet S et al. Concomitant administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 2001; 15: 1941-1949.
50. Santini G, Salvagno L, Leoni P et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group. J Clin Oncol 1998; 16: 2796-2802.
51. Hamlin PA, Zelenetz AD, Kewalramani T et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989-1996.
52. Laport GG, Levine BL, Stadtmauer EA et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 2003; 102: 2004-2013.
53. Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphomia: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288-1294.
54. Gianni AM, Magni M, Martellu M et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102: 749-755.
55. Romaguera JE, Khouri IF, Kantarjian HM et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000; 39: 77-85.
56. Romaguera JE, Cabanillas F, Dang NH et al. Mantle cell lymphoma (MCL) - high rates of complete remission (CR) and prolonged failure-free survival (FFS) with Rituxan-hyperCVAD (R-HCVAD) without stem cell transplant (SCT). Blood 2001; 98 (Suppl 1): 3030a.
57. Lefrere F, Delmer A, Suzan F et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16: 587-593.
58. Gopal AK, Rajendran JG, Petersdorf SH et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158-3162.
59. Vandenberghe E, Ruiz de Elvira C, Loberiza. FR et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793-800.
60. Wilson WH, Neelapu S, White T et al. Phase II study of idiotype vaccine following EPOCH-Rituximab treatment in untreated mantle-cell lymphoma. Ann Oncol 2002; 13 (Suppl 2): 9.
61. Bendandi M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Expert Rev Anticancer Ther 2001; 1: 65-72.
62. Lynch JW, Hei DL, Braylan RC et al. Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-Hodgkin's lymphoma. Am J Clin Oncol 2002; 25: 391-397.
63. Hunault-Berger M, Ifrah N, Solal-Celigny P et al. Intensive therapies in follicular non-Hodgkin lymphomas. Blood 2002; 100: 1141-1152.
64. Williams CD, Harrison CN, Lister TA et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001; 19: 727-735.
65. Forrest DL, Thompson K, Nevill TJ et al. Allogenic hematopoietic stem cell transplantation for progressive follicular lymphoma. Bone Marrow Transplant 2002; 29: 973-978.
66. Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogenic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-3599.
67. Hainsworth JD, Burris HA 3rd, Morrissey LH et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95: 3052-3056.
68. Colombat P, Salles G, Brousse N et al. Rituximiab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-106.
69. Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856-862.
70. Czuczman MS, Fallon A, Mohr A et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002; 29: 36-40.
71. Friedberg JW, Neuberg D, Gribben JG et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002; 117: 828-834.
72. Wiseman GA, Gordon LI, Multani PS et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336-4342.
73. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463.
74. Witzig TE, Flinn IW, Gordon LI et al. Treatment With ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-3269.
75. Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19: 3918-3928.
76. Kwak LW, Campbell MJ, Czerwinski DK et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327: 1236-1237.
77. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171-1177.
78. Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 1997; 89: 3129-3135.
79. Timmermann JM. Vaccine therapies for non-Hodgkin's lymphoma. Curr Treat Options Oncol 2002; 3: 307-315.
80. Timmermann JM, Czerwinski DK, Davis TA et al. Idiotype-pulse dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517-1526.
81. Federico M, Vitolo U, Zinzani PL et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95: 783-789.
82. Isaacson PG, Wright D. Malignant of mucosa-associated lymphoid tissue: a distinctive type of B-cell lymphoma. Cancer 1983; 52: 1410-1416.
83. Isaacson PG, Wright D. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer 1984; 53: 2515-2524.
84. Isaacson PG. Extranodal lymphomas: the MALT concept. Verh Dtsch Ges Pathol 1992; 76: 14-23.
85. Isaacson PG. The MALT lymphoma concept updated. Ann Oncol 1995; 6: 319-320.
86. Zucca E, Bertoni F, Roggero E et al. The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000; 96: 410-419.
87. Hyjek E, Isaacson PG. Primary B cell lymphoma of the thyroid and its relationship to Hashimoto's thyroiditis. Hum Pathol 1988; 19: 1315-1326.
88. Hyjek E, Smith WJ, Isaacson PG. Primary B-cell lymphoma of salivary glands and its relationship to myoepithelial sialaenitis. Hum Pathol 1988; 19: 766-776.
89. Thieblemont C, Bastion Y, Berger F et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma. behavior: Analysis of 108 patients. J Clin Oncol 1997; 15: 1624-1630.
90. Thieblemont C, Berger F, Dumontet C et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000; 95: 802-806.
91. Zinzani PL, Magagnoli M, Galieni P et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 1999; 17: 1254-1258.
92. Zucca E, Roggero E, Bertoni F et al. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997; 8: 727-737.
93. Zucca E, Roggero E, Bertoni F et al. Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol 1999; 10: 1023-1033.
94. Kaplan MA, Pettit CL, Zukerberg LR et al. Primary lymphoma of the trachea with morphologic and inummophenotypic characteristics of low-grade B-cell lymphoma mucosa-associated lymphoid tissue. Am J Surg Pathol 1992; 16: 71-75.
95. Nicholson AG, Wotherspoon AC, Diss TC et al. Pulmonary B-cell non-Hodgkin's lymphomas: the value of immunohistochemistry and gene analysis in diagnosis. Histopathology 1995; 26: 395-403.
96. Isaacson PG, Chan JKC, Tang C et al. Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue arising in the thymus: a thymic lymphoma mimicking myoepithelial sialadenitis. Am J Surg Pathol 1990; 14: 342-351.
97. Mattia AR, Ferry JA, Harris NL. Breast lymphoma: a B-cell spectrum including the low-grade B-cell lymphoma of mucosa accosiated lymphoid tissue. Am J Surg Pathol 1993; 17: 574-587.
98. Bailey EM, Ferry JA, Harris NL et al. Marginal zone lymphoma (low grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue. Am J Surg Pathol 1996; 20: 1011-1023.
99. Isaacson PG, Banks PM, Best PV et al. Primary low-grade hepatic B-cell lymphoma of mucosa-associated lymphoid tissue (MALT)-type. Am J Surg Pathol 1995; 19: 571-575.
100. Wotherspoon AC, Hardman-Lea S, Isaacson PG. Mucosa-associated lymphoid tissue (MALT) in the human conjunctiva. J Pathol 1994; 174: 33-37.
101. Parveen T, Navarro-Roman L, Medeiros LJ et al. Low-grade B-cell lymphoma of mucosa-associated lymphoid tiddue arising in the kidney. Arch Pathol Lab Med 1993; 117: 780-783.
102. Cavalli F, Isaacson PG, Gascoyne RD et al. Malt lymphomas. Hematology (Am Soc Hematol Educ Program) 2001; 241-258.
103. Hitchcock S, Ng Ak, Fisher DC et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2002; 52: 1058-1066.
104. Bayerdorffer E, Neubauer A, Rudolph B et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma, Study Group. Lancet 1995; 345: 1591-1594.
105. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy-Lancet 2001; 357: 39-40.
106. Liu H, Ye H, Ruskone-Fourmestraux A et al. t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286-1294.
107. Liu H, Ye H, Dogan A et al. t(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 2001; 98: 1182-1187.
108. Starostik P, Patzner J, Greiner A et al. Gastric marginal zone B-cell lymphomas of MALT type develop along two distinct pathogenetic pathways. Blood 2002; 99: 3-9.
109. Remstein ED, Kurtin PJ, James CD et al. Mucosa-associated lymphoid tissue lymphomas with t(11;18)(q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways. Am J Pathol 2002; 161: 63-71.
110. Conconi A, Martinelli G, Thieblemont C et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102: 2741-2745.